Interventional Oncology Devices – Market Insights – Japan

Although the interventional oncology procedure volumes are increasing marginally in Japan, the Japanese interventional oncology device market will decline due to limited adoption of minimally invasive interventional oncology procedures, substantiated by Japanese guidelines, stringent device approval process, biennial reimbursement cuts, declining overall population, and increasing developments in anticancer drugs.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for interventional oncology devices in Japan from 2019 to 2033.

Clinical guidelines influence the adoption of interventional oncology devices in Japan.

Which devices are favored by the clinical guidelines?

What are the recent revisions in the clinical guidelines, and how will they impact the adoption of various devices in the Japanese market?

How the revision in the clinical guidelines will impact the competitors in the market?

Reimbursement will be an important factor in the adoption of interventional oncology procedures in Japan.

What is the reimbursement scenario in the country, and how will it impact the adoption of interventional oncology devices in this market?

Which devices are most impacted by the biennial reimbursement cuts in this market?

Positive clinical data will play an important role in driving the adoption of interventional oncology devices.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on the market dynamics and device adoption?

Stringent regulatory framework and device approval delays will impact the interventional oncology device market in Japan.

How have regulatory approval delays impacted the Japanese interventional oncology device market?

Which devices are anticipated to enter the Japanese market within the forecast period?

Market dynamics will change over the forecast period with anticipated entry of novel devices in this market.

What are the recent developments in the IRE device and radioembolization sphere spaces, and how have those developments impacted estimated launch of these products?